MPM Oncology Impact Management »

Urogen Pharma shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Urogen Pharma (URGN) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Urogen Pharma

Tip: Access up to 7 years of quarterly data

All positions including Urogen Pharma held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Urogen Pharma by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $22M 941k 23.42
2025-09-30 $2.7M 135k 19.95

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Urogen Pharma

Rtw Investments
Paradigm Biocapital Advisors
Toronto-Dominion Bank
BlackRock
Leucadia National Corporation
Silverarc Capital Management
Millennium Management
SG Americas Securities
American Century Companies
Acorn Capital Advisors
Menora Mivtachim Holdings
Healthcare Of Ontario Pension Plan Trust Fund
Caption Management
MPM Oncology Impact Management
D. E. Shaw & Co

View all funds holding Urogen Pharma